Marex Group’s Taysha Gene Therapies TSHA Stock Holding History

Marex Group’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,500	Closed	-$28.9K	–	1003
2025 Q2	$28.9K	Hold	12,500	–	–	﹤0.01%	613
2025 Q1	$17.4K	Hold	12,500	–	–	﹤0.01%	667
2024 Q4	$21.6K	Hold	12,500	–	–	﹤0.01%	658
2024 Q3	$25.1K	Hold	12,500	–	–	﹤0.01%	577
2024 Q2	$28K	Buy	+12,500	New	+$36.4K	﹤0.01%	605

Other funds holding TSHA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Marex Group's TSHA Position: Q3 2025 in Review

Marex Group sold out of Taysha Gene Therapies (TSHA) in Q3 2025, closing a stake of 12,500 shares — an estimated $28.9K sold.

Marex Group first reported a position in TSHA in Q2 2024 and held it in 5 quarters. The position peaked at $28.9K in Q2 2025. 155 funds tracked by Wall St. Rank hold TSHA as of Q3 2025.

Marex Group reported no remaining Taysha Gene Therapies position as of Q3 2025 after selling out during the quarter.
Marex Group sold 12,500 Taysha Gene Therapies shares in Q3 2025, an estimated $28.9K.
Marex Group first reported a position in Taysha Gene Therapies in Q2 2024 and held it in 5 quarters.
Marex Group's Taysha Gene Therapies position peaked at $28.9K in Q2 2025.
155 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.